Shareholders Approve Reverse Stock Split to Address Nasdaq Delisting Threat

summarizeSummary

Cue Biopharma shareholders approved a reverse stock split, empowering the Board to implement a ratio between 1-for-30 and 1-for-50 to address the company's Nasdaq delisting threat.

check_boxKey Events

• Reverse Stock Split Approved

  Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-30 and 1-for-50, at the Board's discretion. This is a direct response to the previously disclosed Nasdaq delisting threat.

• Board of Directors Elected

  Six nominees (Pasha Sarraf, Peter A. Kiener, Frank Morich, Pamela Garzone, Patrick Verheyen, and Jill Broadfoot) were elected to the Board of Directors. Votes for former CEO Usman Azam were disregarded following his resignation on March 26, 2026, as previously announced.

• Auditor Ratified

  Shareholders ratified the appointment of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Executive Compensation Approved

  A non-binding advisory proposal on the compensation of the company's named executive officers was approved by stockholders.

auto_awesomeAnalysis

Shareholders have approved a reverse stock split, granting the Board discretion to implement a ratio between 1-for-30 and 1-for-50. This action is a critical step for Cue Biopharma, which previously disclosed substantial doubt about its ability to continue as a going concern and an active Nasdaq delisting threat in its March 16, 2026 10-K filing. The reverse split is intended to increase the per-share price to meet Nasdaq's minimum bid requirements, thereby mitigating the delisting risk and providing a pathway for continued listing. While the underlying financial challenges remain, this approval removes uncertainty regarding the company's ability to address a key compliance issue.